[
  {
    "ts": null,
    "headline": "Fidelity Contrafund Q4 2024 Review",
    "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500Â® index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738794900,
      "headline": "Fidelity Contrafund Q4 2024 Review",
      "id": 132569795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/952762622/image_952762622.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024, the Fidelity Contrafund's Retail Class shares gained 3.56%, topping the 2.41% advance of the S&P 500Â® index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3a0a5a73483fa9fd7e332d0b4cf17231696a722fb5cfb954e54a0be6eb6011ff"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)",
    "summary": "Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=c964cf4a3b1ab972ec47e0826d1246cae4dd1a3013683d744db7f02d83da5dfd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738755928,
      "headline": "Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)",
      "id": 132563230,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1186092495/image_1186092495.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=c964cf4a3b1ab972ec47e0826d1246cae4dd1a3013683d744db7f02d83da5dfd"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
    "summary": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
    "url": "https://finnhub.io/api/news?id=2fa33e571cd7d8d171ed1b76da7625eeca848b707eeb38aae975165b4458e3d8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738754040,
      "headline": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
      "id": 132564451,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA",
      "url": "https://finnhub.io/api/news?id=2fa33e571cd7d8d171ed1b76da7625eeca848b707eeb38aae975165b4458e3d8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today",
    "summary": "Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.",
    "url": "https://finnhub.io/api/news?id=8f01c95d1cca4944d0b96bac91965e0bcb3286752ac3796055c8f8c08ee49963",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738750393,
      "headline": "Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today",
      "id": 132562777,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.",
      "url": "https://finnhub.io/api/news?id=8f01c95d1cca4944d0b96bac91965e0bcb3286752ac3796055c8f8c08ee49963"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
    "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738746600,
      "headline": "Fidelity Blue Chip Growth Fund Q4 2024 Commentary",
      "id": 132562503,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397047877/image_1397047877.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024, the Fidelity Blue Chip Growth Fund's Retail Class shares gained 9.12%, handily outpacing the benchmark. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=3fe7acc1f518c5b79647875f00651e8380ca832b0db7920c13dff2215f8c56ae"
    }
  },
  {
    "ts": null,
    "headline": "Merck Is Suffering From a Classic Pharma Problem",
    "summary": "Merck Is Suffering From a Classic Pharma Problem",
    "url": "https://finnhub.io/api/news?id=9c176806575301aa39a2825c11115e2067f62d0cadf52008873bf924f3d6328e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738738800,
      "headline": "Merck Is Suffering From a Classic Pharma Problem",
      "id": 132564431,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Merck Is Suffering From a Classic Pharma Problem",
      "url": "https://finnhub.io/api/news?id=9c176806575301aa39a2825c11115e2067f62d0cadf52008873bf924f3d6328e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly needs a plan to spur weight-loss drug sales, investors say",
    "summary": "Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast...",
    "url": "https://finnhub.io/api/news?id=4798dcc49968562922078cd105cdb3ec18007a0c8a0a4365060c496d77853428",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738735402,
      "headline": "Lilly needs a plan to spur weight-loss drug sales, investors say",
      "id": 132560430,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast...",
      "url": "https://finnhub.io/api/news?id=4798dcc49968562922078cd105cdb3ec18007a0c8a0a4365060c496d77853428"
    }
  },
  {
    "ts": null,
    "headline": "J.P. Morgan Healthcare Conference 2025: Healthcare's Roadmap For The Year Ahead",
    "summary": "Major deals, including Johnson & Johnsonâs $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly $1T in industry financial capacity. Read more here.",
    "url": "https://finnhub.io/api/news?id=219da7f2b4534954405d56142bfd8fa2b7e3bf9f3d5cf0ec4011110a20f106f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738720500,
      "headline": "J.P. Morgan Healthcare Conference 2025: Healthcare's Roadmap For The Year Ahead",
      "id": 132559368,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/956800254/image_956800254.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Major deals, including Johnson & Johnsonâs $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly $1T in industry financial capacity. Read more here.",
      "url": "https://finnhub.io/api/news?id=219da7f2b4534954405d56142bfd8fa2b7e3bf9f3d5cf0ec4011110a20f106f1"
    }
  }
]